February 04, 2015
1 min read

Belsomra is available as insomnia treatment in the US

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Belsomra is now being marketed for the treatment of insomnia, according to a press release issued by Merck.

The FDA approved Belsomra (suvorexant, Merck Sharp Dohme) tablets in four different strengths (5, 10, 15 and 20 mg), in August 2014.

Three clinical trials that included more than 500 patients demonstrated the medication’s effectiveness at improving insomnia.

Belsomra is contraindicated in patients with narcolepsy, contains a Schedule IV controlled substance and can impair daytime wakefulness, according to the press release.